Genetically engineered mouse models of Parkinson's disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting more than 1% of the population over age 60. The most common feature of PD is a resting tremor, though there are many systemic neurological effects, such as incontinence and sleep disorders. PD is histopathologically identified by the presence of Lewy bodies (LB), proteinaceous inclusions constituted primarily by α-synuclein. To date, there is no effective treatment to slow or stop disease progression. To help understand disease pathogenesis and identify potential therapeutic targets, many genetic mouse models have been developed. By far the most common of these models are the wildtype and mutant α-synuclein transgenic mice, because α-synuclein was the first protein shown to have a direct effect on PD pathogenesis and progression. There are many other gene-disrupted or -mutated models currently available, which are based on genetic anomalies identified in the human disease. In addition, there are also models which examine genes that may contribute to disease onset or progression but currently have no identified causative PD mutations. These genes are part of signaling pathways important for maintaining neuronal function in the nigrostriatal pathway. This review will summarize the most commonly used of the genetic mouse models currently available for PD research. We will examine how these models have expanded our understanding of PD pathogenesis and progression, as well as aided in identification of potential therapeutic targets in this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 6×
“[1 27 ] TH + SN n eu ro d eg en er at io n ,”
BackgroundInfluentialMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“It has been demonstrated that synuclein can cause inflammation leading to reactive gliosis both in vitro and in vivo [93,165,194].”
BackgroundSelf-citationRamirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913 · cited 2×
“Parkin is an E3 ubiquitin ligase and mutations in the gene are the most common cause of juvenile Parkinsonism; however, the corresponding mouse models with Parkin deficiency showed only a mild or no phenotype without any loss of dopaminergic neurons [68;69].”
BackgroundLee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 1×
“Additionally, evidence for transmission of -synuclein from neurons to glia resulting in subsequent formation of glial -synuclein inclusions [95] in wildtype synuclein transgenic mice [112] has demonstrated a mechanism for both early and sustained inflammation in response to increased -synuclein levels.”
BackgroundGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 1×
“Zhang / Brain Research Bulletin 88 (2012) 13– 32 25 exhibited significantly altered HVA/DOPAC ratios, but despite the alterations observed in DA metabolism, neither male nor female mice were found to have an overt Parkinsonian phenotype, though several non-Parkinsonian behavioral abnormalities were noted [63].”
BackgroundPathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739 · cited 1×
“6-OHDA has been used to model PD though a dual mechanisms of increasing ROS and quinines in the catacholaminergic system [10].”
MethodLoss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress
Gautier, C. A., Kitada, T., & Shen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802076105 · Cited by 698 · cited 3×
“Abnormal mitochondrial morphology with increased ROS has been reported in many PD mouse models including the parkin knockout [128,146], PINK1 knockout [57,62], and DJ-1knockout [71,76,83].”
BackgroundGlucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684 · cited 1×
“Additionally, these mice were later found to develop mitochondrial degeneration (as seen by p53 co-localization, mitochondrial DNA damage, and enlarged, swollen mitochondria) concomitant with -synuclein inclusion development [107].”
BackgroundVogiatzi, T., Xilouri, M., Vekrellis, K., & Stefanis, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801992200 · Cited by 683
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605 · cited 2×
“MitoPark mice developed an adult-onset, slow-progressing, Parkinsonian phenotype which included motor impairment, intraneuronal inclusions, and SN cell death [109].”
BackgroundMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597 · cited 10×
“[3 9] Tr em or , r ig id it y”
BackgroundInfluentialSpencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., & Masliah, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4390-09.2009 · Cited by 595 · cited 3×
“Finally, stereotactic injection of beclin 1, a key regulator in the macroautophagy pathway, was shown to reduce neurodegeneration in this model of synucleinopathy [158], highlighting one potential method for therapeutic intervention.”
BackgroundInfluentialQin, L., Liu, Y., Wang, T., Wei, S.-J., Block, M. L., Wilson, B., Liu, B., & Hong, J.-S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307657200 · Cited by 574 · cited 1×
“A large body of evidence implicates inflammation and concomitant microglial activation in perpetuating PD neuropathology [55,93,141–146,165].”
BackgroundRockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502 · cited 3×
“PD models with -synuclein gene modifications Early genetic models of PD focused on -synuclein (the snca gene) [47,96,112,143,144,165], including wildtype and autosomal dominant mutations in the protein which lead to early onset PD with a more aggressive progression and clinical pathology [24,79,121].”
BackgroundParkin-deficient mice are not a robust model of parkinsonism
Perez, F. A., & Palmiter, R. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409598102 · Cited by 477 · cited 1×
“Parkin is an E3 ubiquitin ligase and mutations in the gene are the most common cause of juvenile Parkinsonism; however, the corresponding mouse models with Parkin deficiency showed only a mild or no phenotype without any loss of dopaminergic neurons [68;69].”
BackgroundSynuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 3×
“Although there was no obvious SN dopaminergic neurodegeneration, significant microglial activation was found in the brains of α-synuclein transgenic mice as young as one month [18].”
BackgroundClearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445 · cited 2×
“In fact, the autophagy lysosome pathway has been repeatedly shown to play a key role in -synuclein degradation [28,94,105,140,179], reviewed in [150], including the degradation of -synuclein aggregates [187,191].”
BackgroundDegradation of α-Synuclein by Proteasome
Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., & Mouradian, M. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.33855 · Cited by 417
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K., & Mizuno, Y. (1998) · Neurology · doi:10.1212/wnl.51.3.890 · Cited by 370
Bedford, L., Hay, D., Devoy, A., Paine, S., Powe, D. G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2218-08.2008 · Cited by 327 · cited 2×
“Loss of TH-positive neurons was observed as well as increased GFAP activation [64].”
BackgroundBehavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285 · cited 7×
“These mice exhibited age-dependent decreases in DA and its metabolites accompanied by impairments in motor coordination with abnormal axons and terminals [143].”
BackgroundInfluentialMatsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Picciano, M., LaFrancois, J., Yu, X., Dickson, D., Langston, W. J., McGowan, E., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0392 · Cited by 281
The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235 · cited 1×
“The bacterial endotoxin LPS models the inflammatory aspect of PD, causing glial activation (via binding of TLR-4 receptors) which in turn causes release of proinflammatory cytokines and free radicals with subsequent dopaminergic neurodegeneration [9].”
BackgroundZecca, L., Wilms, H., Geick, S., Claasen, J.-H., Brandenburg, L.-O., Holzknecht, C., Panizza, M. L., Zucca, F. A., Deuschl, G., Sievers, J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0361-7 · Cited by 205
Yu, W. H., Dorado, B., Figueroa, H. Y., Wang, L., Planel, E., Cookson, M. R., Clark, L. N., & Duff, K. E. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080928 · Cited by 155 · cited 1×
“In fact, the autophagy lysosome pathway has been repeatedly shown to play a key role in -synuclein degradation [28,94,105,140,179], reviewed in [150], including the degradation of -synuclein aggregates [187,191].”
BackgroundA molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145
Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity
Su, X., Federoff, H. J., & Maguire-Zeiss, K. A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9053-x · Cited by 145
Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice
Kitada, T., Pisani, A., Karouani, M., Haburcak, M., Martella, G., Tscherter, A., Platania, P., Wu, B., Pothos, E. N., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06152.x · Cited by 125 · cited 3×
“[1 84 ] N ot re p or te d N o TH + SN ce ll lo ss u p to 1”
BackgroundInfluentialLou, H., Montoya, S. E., Alerte, T. N. M., Wang, J., Wu, J., Peng, X., Hong, C.-S., Friedrich, E. E., Mader, S. A., Pedersen, C. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100867 · Cited by 115
Autolysosomal Membrane-associated Betaine Homocysteine Methyltransferase
Ueno, T., Ishidoh, K., Mineki, R., Tanida, I., Murayama, K., Kadowaki, M., & Kominami, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15222 · Cited by 50
Cited by
Impact of intermittent fasting on health and disease processes
Mattson, M. P., Longo, V. D., & Harvie, M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.005 · Cited by 1,187
Intermittent and periodic fasting, longevity and disease
Longo, V. D., Di Tano, M., Mattson, M. P., & Guidi, N. (2021) · Nature Aging · doi:10.1038/s43587-020-00013-3 · Cited by 286
Circadian dysregulation in Parkinson's disease
Videnovic, A., & Golombek, D. (2017) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.11.001 · Cited by 63
“Another approach involves genetic manipulation of some of the key molecular regulators related to the development of PD (Crabtree and Zhang, 2012).”
BackgroundReyes, J. F., Ekmark-Léwen, S., Perdiki, M., Klingstedt, T., Hoffmann, A., Wiechec, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I., Ingelsson, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01136-3 · Cited by 59
“Thus, the accumulation of liver α-syn appears to correlate with the amount of α-syn deposition within the brain of these synucleinopathy models [60].”
BackgroundNeuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Metadata
- Authors
- Crabtree, D. M., & Zhang, J.
- Venue
- Brain Research Bulletin
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 88
- Issue
- 1
- Pages
- 13-32
- ISSN
- 0361-9230 (ISSN-L)
- OpenAlex
- W2041116500
- Cited by
- 70
- References
- 39
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.